Boom! Acrivon's AP3 platform news is finally getting the street's attention. 🧪 That 70+ RSI is hot, but the monster volume and WMA breakout scream this isn't a drill. The market is pricing in real clinical potential. This looks like a BUY-the-momentum play. #BiotechRising

"ACRV’s been beaten down (-70% in a month!), but hold up—this isn’t a dumpster fire. 🧐 The news is spicy: clinical wins, a rockstar CMO hire, and AACR buzz. RSI’s flirting with oversold (31), and volume spiked on that 1.29 high today—someone’s bargain hunting. 9-day EMA’s creeping toward a golden cross. If you believe in biotech turnarounds, this screams BUY-the-dip energy. Just pack patience—it’s a rollercoaster. #BiotechBets"

The stock of Acrivon Therapeutics (ACRV) has shown a bullish trend over the last 24 hours, with the price fluctuating between lows of $2.51 and highs of $2.71. The closing price was $2.53, indicating some resistance at the $2.50 level. The volume has been relatively consistent throughout the day, with some spikes indicating increased interest at certain price levels. The RSI is currently in a neutral state, suggesting that the stock may not be overbought or oversold. The news surrounding Acrivon Therapeutics seems to be positive, with updates on their AP3 platform capabilities, clinical programs, and positive data from their endometrial cancer studies. This positive sentiment from the news could be contributing to the bullish trend in the stock price. Investors may want to keep an eye on key support and resistance levels, particularly around $2.50 and $2.71, as well as monitor volume trends for potential confirmation of the current uptrend.